Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability

Cyrille J. Cohen, Yangbing Zhao, Zhili Zheng, Steven A. Rosenberg, Richard A. Morgan

Research output: Contribution to journalArticle

Abstract

Little is known about the biology of murine T-cell receptors (TCR) expressed in human cells. We recently observed that a murine anti-human p53 TCR is highly functional when expressed in human lymphocytes. Herein, we compare human and mouse TCR function and expression to delineate the molecular basis for the apparent superior biological activity of murine receptors in human T lymphocytes. To this end, we created hybrid TCRs where we swapped the original constant regions with either human or mouse ones, respectively. We showed that murine or "murinized" receptors were overexpressed on the surface of human lymphocytes compared with their human/humanized counterparts and were able to mediate higher levels of cytokine secretion when cocultured with peptide-pulsed antigen-presenting cells. Preferential pairing of murine constant regions and improved CD3 stability seemed to be responsible for these observations. These enhanced biological properties translated into significantly greater antitumor response mediated by TCR with mouse constant regions. Furthermore, we were able to circumvent the natural low avidity of class I MHC TCR in CD4+ cells by introducing the murinized TCR into CD4 + lymphocytes, giving them the ability to recognize melanoma tumors. These findings have implications for human TCR gene transfer therapy and may provide new insights into the biology of the TCR/CD3 complex.

Original languageEnglish (US)
Pages (from-to)8878-8886
Number of pages9
JournalCancer Research
Volume66
Issue number17
DOIs
StatePublished - Sep 1 2006
Externally publishedYes

Fingerprint

Hybrid Cells
T-Cell Antigen Receptor
Human Activities
Lymphocytes
CD3 Antigens
T-Cell Receptor Genes
Antigen-Presenting Cells
Genetic Therapy
Melanoma
Cytokines
T-Lymphocytes
Peptides

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. / Cohen, Cyrille J.; Zhao, Yangbing; Zheng, Zhili; Rosenberg, Steven A.; Morgan, Richard A.

In: Cancer Research, Vol. 66, No. 17, 01.09.2006, p. 8878-8886.

Research output: Contribution to journalArticle

Cohen, Cyrille J. ; Zhao, Yangbing ; Zheng, Zhili ; Rosenberg, Steven A. ; Morgan, Richard A. / Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. In: Cancer Research. 2006 ; Vol. 66, No. 17. pp. 8878-8886.
@article{b3540062146a4e9188d33d2ffd1f73ba,
title = "Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability",
abstract = "Little is known about the biology of murine T-cell receptors (TCR) expressed in human cells. We recently observed that a murine anti-human p53 TCR is highly functional when expressed in human lymphocytes. Herein, we compare human and mouse TCR function and expression to delineate the molecular basis for the apparent superior biological activity of murine receptors in human T lymphocytes. To this end, we created hybrid TCRs where we swapped the original constant regions with either human or mouse ones, respectively. We showed that murine or {"}murinized{"} receptors were overexpressed on the surface of human lymphocytes compared with their human/humanized counterparts and were able to mediate higher levels of cytokine secretion when cocultured with peptide-pulsed antigen-presenting cells. Preferential pairing of murine constant regions and improved CD3 stability seemed to be responsible for these observations. These enhanced biological properties translated into significantly greater antitumor response mediated by TCR with mouse constant regions. Furthermore, we were able to circumvent the natural low avidity of class I MHC TCR in CD4+ cells by introducing the murinized TCR into CD4 + lymphocytes, giving them the ability to recognize melanoma tumors. These findings have implications for human TCR gene transfer therapy and may provide new insights into the biology of the TCR/CD3 complex.",
author = "Cohen, {Cyrille J.} and Yangbing Zhao and Zhili Zheng and Rosenberg, {Steven A.} and Morgan, {Richard A.}",
year = "2006",
month = "9",
day = "1",
doi = "10.1158/0008-5472.CAN-06-1450",
language = "English (US)",
volume = "66",
pages = "8878--8886",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "17",

}

TY - JOUR

T1 - Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability

AU - Cohen, Cyrille J.

AU - Zhao, Yangbing

AU - Zheng, Zhili

AU - Rosenberg, Steven A.

AU - Morgan, Richard A.

PY - 2006/9/1

Y1 - 2006/9/1

N2 - Little is known about the biology of murine T-cell receptors (TCR) expressed in human cells. We recently observed that a murine anti-human p53 TCR is highly functional when expressed in human lymphocytes. Herein, we compare human and mouse TCR function and expression to delineate the molecular basis for the apparent superior biological activity of murine receptors in human T lymphocytes. To this end, we created hybrid TCRs where we swapped the original constant regions with either human or mouse ones, respectively. We showed that murine or "murinized" receptors were overexpressed on the surface of human lymphocytes compared with their human/humanized counterparts and were able to mediate higher levels of cytokine secretion when cocultured with peptide-pulsed antigen-presenting cells. Preferential pairing of murine constant regions and improved CD3 stability seemed to be responsible for these observations. These enhanced biological properties translated into significantly greater antitumor response mediated by TCR with mouse constant regions. Furthermore, we were able to circumvent the natural low avidity of class I MHC TCR in CD4+ cells by introducing the murinized TCR into CD4 + lymphocytes, giving them the ability to recognize melanoma tumors. These findings have implications for human TCR gene transfer therapy and may provide new insights into the biology of the TCR/CD3 complex.

AB - Little is known about the biology of murine T-cell receptors (TCR) expressed in human cells. We recently observed that a murine anti-human p53 TCR is highly functional when expressed in human lymphocytes. Herein, we compare human and mouse TCR function and expression to delineate the molecular basis for the apparent superior biological activity of murine receptors in human T lymphocytes. To this end, we created hybrid TCRs where we swapped the original constant regions with either human or mouse ones, respectively. We showed that murine or "murinized" receptors were overexpressed on the surface of human lymphocytes compared with their human/humanized counterparts and were able to mediate higher levels of cytokine secretion when cocultured with peptide-pulsed antigen-presenting cells. Preferential pairing of murine constant regions and improved CD3 stability seemed to be responsible for these observations. These enhanced biological properties translated into significantly greater antitumor response mediated by TCR with mouse constant regions. Furthermore, we were able to circumvent the natural low avidity of class I MHC TCR in CD4+ cells by introducing the murinized TCR into CD4 + lymphocytes, giving them the ability to recognize melanoma tumors. These findings have implications for human TCR gene transfer therapy and may provide new insights into the biology of the TCR/CD3 complex.

UR - http://www.scopus.com/inward/record.url?scp=33749005425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749005425&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-06-1450

DO - 10.1158/0008-5472.CAN-06-1450

M3 - Article

VL - 66

SP - 8878

EP - 8886

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 17

ER -